Axsome Therapeutics, Inc.
US ˙ NasdaqGM ˙ US05464T1043

Introduction

This page provides a comprehensive analysis of the known insider trading history of Mark Coleman. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Mark Coleman has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:AXSM / Axsome Therapeutics, Inc. Director 48,212
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Mark Coleman. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases AXSM / Axsome Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AXSM / Axsome Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2025-09-08 AXSM Coleman Mark 800 127.2000 800 127.2000 101,760 0 129.2900 1,672 1.64
2025-09-08 AXSM Coleman Mark 287 127.3000 287 127.3000 36,535
2025-09-08 AXSM Coleman Mark 488 127.4000 488 127.4000 62,171
2021-11-18 AXSM Coleman Mark 409 35.0700 409 35.0700 14,344
2021-11-18 AXSM Coleman Mark 1,021 35.1000 1,021 35.1000 35,837
2021-05-12 AXSM Coleman Mark 500 58.1500 500 58.1500 29,075
2020-06-29 AXSM Coleman Mark 650 78.5000 650 78.5000 51,025
2019-06-26 AXSM Coleman Mark 15,800 23.1000 15,800 23.1000 364,980
2019-06-25 AXSM Coleman Mark 400 23.2500 400 23.2500 9,300
2019-05-13 AXSM Coleman Mark 4,650 21.4400 4,650 21.4400 99,696
2019-03-19 AXSM Coleman Mark 5,100 12.1800 5,100 12.1800 62,118

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AXSM / Axsome Therapeutics, Inc. Insider Trades
Insider Sales AXSM / Axsome Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AXSM / Axsome Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-05-20 AXSM Coleman Mark 3,000 107.4910 3,000 107.4910 322,473 69 100.3900 -21,303 -6.61

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AXSM / Axsome Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Mark Coleman as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-09-09 2025-09-08 4 AXSM Axsome Therapeutics, Inc.
Common Stock
P - Purchase 488 48,212 1.02 127.40 62,171 6,142,209
2025-09-09 2025-09-08 4 AXSM Axsome Therapeutics, Inc.
Common Stock
P - Purchase 287 47,724 0.61 127.30 36,535 6,075,265
2025-09-09 2025-09-08 4 AXSM Axsome Therapeutics, Inc.
Common Stock
P - Purchase 800 47,437 1.72 127.20 101,760 6,033,986
2025-05-29 2025-05-28 4 AXSM Axsome Therapeutics, Inc.
Common Stock
S - Sale X -3,750 46,637 -7.44 103.43 -387,862 4,823,665
2025-05-29 2025-05-27 4 AXSM Axsome Therapeutics, Inc.
Common Stock
S - Sale X -3,750 50,387 -6.93 105.47 -395,512 5,314,317
2025-05-20 2025-05-20 4 AXSM Axsome Therapeutics, Inc.
Common Stock
S - Sale -3,000 54,137 -5.25 107.49 -322,473 5,819,240
2025-01-06 2025-01-03 4 AXSM Axsome Therapeutics, Inc.
Common Stock
M - Exercise 9,127 57,137 19.01 9.00 82,143 514,233
2024-11-20 2024-11-19 4 AXSM Axsome Therapeutics, Inc.
Common Stock
M - Exercise 33,410 48,010 228.84 5.94 198,455 285,179
2024-05-29 2024-05-29 4 AXSM Axsome Therapeutics, Inc.
Common Stock
S - Sale X -5,248 14,600 -26.44 75.14 -394,333 1,097,038
2024-05-29 2024-05-28 4 AXSM Axsome Therapeutics, Inc.
Common Stock
S - Sale X -5,249 19,848 -20.91 75.21 -394,775 1,492,758
2023-09-15 2023-09-15 4 AXSM Axsome Therapeutics, Inc.
Common Stock
S - Sale X -18,572 403,856 -4.40 75.18 -1,396,189 30,360,723
2023-09-15 2023-09-15 4 AXSM Axsome Therapeutics, Inc.
Common Stock
S - Sale X -11,016 25,097 -30.50 75.19 -828,241 1,886,925
2023-09-15 2023-09-15 4 AXSM Axsome Therapeutics, Inc.
Common Stock
M - Exercise X 11,016 36,113 43.89 3.67 40,429 132,535
2023-01-04 2023-01-03 4 AXSM Axsome Therapeutics, Inc.
Common Stock
M - Exercise 17,501 25,097 230.40 1.30 22,751 32,626
2022-03-17 2022-03-15 4 AXSM Axsome Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise -3,496 17,501 -16.65
2022-03-17 2022-03-15 4 AXSM Axsome Therapeutics, Inc.
Common Stock
M - Exercise 3,496 7,596 85.27 1.30 4,545 9,875
2022-03-08 2022-03-04 4 AXSM Axsome Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 2,798 2,798
2021-11-22 2021-11-18 4 AXSM Axsome Therapeutics, Inc.
Common Stock
P - Purchase 1,021 422,428 0.24 35.10 35,837 14,827,223
2021-11-22 2021-11-18 4 AXSM Axsome Therapeutics, Inc.
Common Stock
P - Purchase 409 421,407 0.10 35.07 14,344 14,778,743
2021-06-08 2021-06-04 4 AXSM Axsome Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 7,325 7,325
2021-05-13 2021-05-12 4 AXSM Axsome Therapeutics, Inc.
Common Stock
P - Purchase 500 420,998 0.12 58.15 29,075 24,481,034
2021-03-09 2021-03-05 4 AXSM Axsome Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 1,201 1,201
2020-08-20 2020-08-19 4 AXSM Axsome Therapeutics, Inc.
Common Stock
G - Gift 397,998 397,998
2020-08-20 2020-08-19 4 AXSM Axsome Therapeutics, Inc.
Common Stock
G - Gift -397,998 5,700 -98.59
2020-06-30 2020-06-29 4 AXSM Axsome Therapeutics, Inc.
Common Stock
P - Purchase 650 403,698 0.16 78.50 51,025 31,690,293
2020-06-05 2020-06-05 4 AXSM Axsome Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 13,000 13,000
2020-03-19 2020-03-17 4 AXSM Axsome Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 3,308 3,308
2019-06-27 2019-06-26 4 AXSM Axsome Therapeutics, Inc.
Common Stock
P - Purchase 15,800 668,848 2.42 23.10 364,980 15,450,389
2019-06-27 2019-06-25 4 AXSM Axsome Therapeutics, Inc.
Common Stock
P - Purchase 400 653,048 0.06 23.25 9,300 15,183,366
2019-06-10 2019-06-07 4 AXSM Axsome Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 13,000 13,000
2019-05-15 2019-05-13 4 AXSM Axsome Therapeutics, Inc.
Common Stock
P - Purchase 4,650 652,648 0.72 21.44 99,696 13,992,773
2019-03-21 2019-03-19 4 AXSM Axsome Therapeutics, Inc.
Common Stock
P - Purchase 5,100 5,100 12.18 62,118 62,118
2019-03-21 2019-03-19 4 AXSM Axsome Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 25,652 25,652
2018-06-05 2018-06-01 4 AXSM Axsome Therapeutics, Inc.
Stock Options (right to buy)
A - Award 13,000 13,000
2018-04-05 2018-03-12 4 AXSM Axsome Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 27,297 27,297
2017-03-17 2017-03-15 4 AXSM Axsome Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 11,000 11,000
2017-03-17 2017-03-15 4 AXSM Axsome Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 26,456 26,456
2016-06-01 2016-05-27 4 AXSM Axsome Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 5,193 5,193
2015-11-24 2015-11-24 4 AXSM Axsome Therapeutics, Inc.
8% Convertible Note
A - Award 140,672 0 -100.00
2015-11-24 2015-11-24 4 AXSM Axsome Therapeutics, Inc.
8% Convertible Note
A - Award 180,526 0 -100.00
2015-11-24 2015-11-24 4 AXSM Axsome Therapeutics, Inc.
8% Convertible Note
A - Award 243,750 0 -100.00
2015-11-24 2015-11-24 4 AXSM Axsome Therapeutics, Inc.
Common Stock
C - Conversion 140,672 647,998 27.73 5.94 835,592 3,849,108
2015-11-24 2015-11-24 4 AXSM Axsome Therapeutics, Inc.
Common Stock
C - Conversion 180,526 507,326 55.24 5.94 1,072,324 3,013,516
2015-11-24 2015-11-24 4 AXSM Axsome Therapeutics, Inc.
Common Stock
C - Conversion 243,750 326,800 293.50 5.40 1,316,250 1,764,720
2015-11-23 2015-11-19 4 AXSM Axsome Therapeutics, Inc.
Employee Stock Option (Right to Buy)
A - Award 9,127 9,127
2015-11-19 3 AXSM Axsome Therapeutics, Inc.
Common Stock
166,100
2015-11-19 3 AXSM Axsome Therapeutics, Inc.
Common Stock
166,100
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)